<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03461445</url>
  </required_header>
  <id_info>
    <org_study_id>1044220</org_study_id>
    <nct_id>NCT03461445</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age&gt;65) Patients</brief_title>
  <official_title>A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age&gt;65) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Veloxis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies have shown that elderly patients experience higher trough levels of
      tacrolimus and are more sensitive to the effects of medications, they experience higher
      occurrence and severity of such medication related toxicities. Therefore, the investigators
      hypothesize that by transitioning patients from tacrolimus immediate release to Envarsus Â®,
      the peak-dose effect will be eliminated or attenuated, leading to a significant decrease in
      neurocognitive toxicities in the older patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will conduct a single-center, prospective, open-label, randomized study to
      evaluate the difference in neurocognitive side effects between Envarsus and immediate release
      tacrolimus. Eligible patients will be enrolled within 8 weeks post-transplantation. They will
      be administered a baseline panel of neurocognitive tests. They will then be randomized to
      either continue on immediate release tacrolimus or Envarsus. 6 weeks after randomization, the
      neurocognitive tests will be repeated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">February 6, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in neurocognitive side effects</measure>
    <time_frame>6 weeks after randomization and baseline testing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in self-reported side effects</measure>
    <time_frame>6 weeks after randomization and baseline testing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tacrolimus dose over concentration ratio</measure>
    <time_frame>6 weeks after randomization and baseline testing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney graft survival</measure>
    <time_frame>6 months after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>6 months after transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Kidney Transplant; Complications</condition>
  <condition>Toxicity</condition>
  <condition>Drug Toxicity</condition>
  <condition>Neurotoxicity</condition>
  <arm_group>
    <arm_group_label>Immediate Release Tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive immediate release tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Envarsus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be converted to Envarsus formulation of tacrolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Envarsus</intervention_name>
    <description>Patients will be randomized to receiving Envarsus instead of IR Tacrolimus</description>
    <arm_group_label>Envarsus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IR Tacrolimus</intervention_name>
    <description>Patients will be randomized to receiving IR Tacrolimus instead of Envarsus</description>
    <arm_group_label>Immediate Release Tacrolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Recipient of a kidney transplant

          2. Age 65 or greater at the time of transplant

          3. Kidney graft is functional (not dialysis dependent) by 4 weeks post-transplant

          4. Have IR tacrolimus as maintenance therapy

          5. Have BMI &lt; 35 at time of transplant

          6. Achieve therapeutic tacrolimus level within 4 weeks post-transplant

        Exclusion Criteria:

          1. Recipient of a simultaneous non-kidney transplant (pancreas)

          2. Had an episode of rejection before study enrollment

          3. Had a TIA/CVA after transplantation and before study enrollment

          4. Had a neurologic injury after transplantation and before study enrollment

          5. Blindness

          6. Have an mTOR inhibitor as maintenance therapy

          7. Nonadherence, as determined by a trough level less than 7 ng/mL after achieving
             therapeutic level with no other rationale for sub-therapeutic levels.

          8. Adults unable to consent

          9. Pregnant women

         10. Prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ling-Xin Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ling-Xin Chen, MD</last_name>
    <phone>916.734.5141</phone>
    <email>lxchen@ucdavis.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling-Xin Chen, MD</last_name>
      <phone>916-734-5141</phone>
      <email>lxchen@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Olivia Moss, RD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Golnaz Friedman, RD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Elderly</keyword>
  <keyword>Neurotoxicity</keyword>
  <keyword>Calcineurin inhibitors</keyword>
  <keyword>Tacrolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

